Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy

Table 3 Multivariable Cox regression analyses predicting overall survival

	All stages	T1	T2	T3	T4
	Multivariable ^a HR (95% CI)	Multivariable ^b HR (95% CI)	Multivariable ^b HR (95% CI)	Multivariable ^b HR (95% CI)	Multivariable ^b HR (95% CI)
LND status
No LND	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
LND	0.87 (0.80–0.95)**	0.98 (0.80–1.19)	0.85 (0.70–1.04)	0.88 (0.78–0.99)*	0.74 (0.59–0.94)*
LND extent
No LND	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
Limited LND	0.90 (0.81–0.99)*	0.98 (0.78–1.25)	0.87 (0.69–1.11)	0.93 (0.81–1.07)	0.73 (0.57–0.94)**
Extended LND	0.83 (0.74–0.94)**	0.97 (0.73–1.30)	0.82 (0.61–1.09)	0.80 (0.68–0.95)*	0.77 (0.57–0.99)*
Lymph node stage
pN0	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
pNx	1.19 (1.08–1.30)***	1.05 (0.86–1.29)	1.20 (0.98–1.48)	1.15 (1.01–1.31)*	1.59 (1.20–2.11)**
pN1–3	2.20 (1.93–2.50)***	2.13 (1.33–3.41)**	2.33 (1.60–3.40)***	2.00 (1.68–2.39)***	2.26 (1.65–3.10)***

*P < 0.05, **P < 0.01, ***P < 0.001. ^a Adjusted to age, gender, race, tumor location, laterality, tumor size, tumor stage, tumor grade, chemotherapy and year of surgery. ^b Adjusted to age, gender, race, tumor location, laterality, tumor size, tumor grade, chemotherapy and year of surgery. HR hazard ratio, 95% CI 95% confidence interval, LND lymph node dissection